1. Short title This Act may be cited as the Pharmaceutical Security Production Act . 2. Commission on Strengthening the Domestic Pharmaceutical Supply Chain (a) Establishment There is established a commission to be known as the Commission on Strengthening the Domestic Pharmaceutical Supply Chain (in this section referred to as the Commission ) to assess the current security and vulnerabilities of the United States pharmaceutical supply chain. (b) Duties The duties of the Commission are the following: (1) Determine concrete timelines and metrics for success for the Pharmaceutical Manufacturing in America program of the Biomedical Advanced Research and Development Authority to produce advanced pharmaceutical ingredients for medicines included in the essential medicines list. (2) Evaluate and identify vulnerabilities in the existing United States pharmaceutical supply chain that could be exploited by foreign adversaries and nonstate actors. (3) Review and propose solutions to strengthen the domestic pharmaceutical manufacturing workforce to support increased production of advanced pharmaceutical ingredients and finished drugs. (4) Assess how Federal health care programs (as defined in section 1128B(f) of the Social Security Act (42 U.S.C. 1320a–7b(f))), the program established under chapter 89 of title 5, United States Code, and provider facilities can be used to create a viable financial market for domestically made advanced pharmaceutical ingredients and finished drug products. (5) Review the successes and failures of Operation Warp Speed and determine if any best practices for public-private partnerships can be used to bolster domestic manufacturing of advanced pharmaceutical ingredients and finished drug products. (6) Estimate the Federal funding necessary to catalyze and strengthen domestic pharmaceutical manufacturing. (7) Identify facilities throughout the United States that can be repurposed to produce advanced pharmaceutical ingredients, especially advanced pharmaceutical ingredients listed on the